Delivering next-generation treatments for back of the eye disorders, with focus on diabetic eye disease

Shareholder information

Oxurion is listed on Euronext Brussels under the symbol OXUR. As of 5 January 2018, Oxurion has a total number of 38,271,575 outstanding shares and a total number of 848,875 warrants. Find more information below about extraordinary and annual shareholders meetings and history of capital.

more info

Analyst Coverage
Conferences & Events
Financial calendar

Check the calendar to learn more about our financial results, general shareholders meetings and business reviews.

  • 07/03/2019
    Full year Results FY 2018
  • 07/05/2019
    Annual Shareholders' Meeting
  • 08/05/2019
    Business Update Q1 2019
  • 05/09/2019
    Half Year Results FY 2019
  • 18/10/2019
    Business Update Q3 FY 2019
Corporate governance

Good corporate governance is key to the success of our company. Read more about the Code of Business Conduct, our Board of Directors and Board Committees.

more info

Perspectives magazine & blog

Looking for more background stories or interviews with scientists and partner organizations? Read more articles on our blog Perspectives or download the magazine!

Visit Perspectives blog

Perspectives magazine

Investor relations contact

Wouter Piepers
Global Head of Corporate Communications and Investor Relations

Gaston Geenslaan 1
B-3001 Heverlee
Belgium
Tel: +32 (0) 16 75 13 10
Cell: +32 478 33 56 32
wouter.piepers@oxurion.com
IR@oxurion.com